Elaphron is pioneering a new therapeutic approach through a novel class of oral, non-systemic therapies designed to address persistent limitations in current standards of care.
Changing the Paradigm of Obesity Treatment: Metabolic Health First
Designed to improve metabolic health while preserving quality of life, physical performance, adequate nutrition, lean mass, and enjoyment of food throughout the weight-loss journey.
Elaphron is developing a new approach to obesity treatment built around a different therapeutic sequence: improving metabolic health first, followed by weight loss.
Current Appetite-Suppressive Therapies
Decreased Food Intake → Energy Deficit → Weight Loss → Improved Metabolic Health
Current appetite-suppressive therapies have transformed obesity care. Their primary therapeutic pathway relies on reducing food intake and creating an energy deficit that drives weight loss, with important improvements in metabolic health and other health-related parameters occurring alongside and following weight reduction.
Metabolic Surgery: Altering Food-Driven Gut Signaling
Metabolic Health Improves First → Weight Loss Follows
Metabolic surgery can have profound and rapid effects on insulin resistance by changing how nutrients interact with the gastrointestinal tract and altering gut-derived metabolic signaling. Improvements in insulin sensitivity and broader metabolic health can occur rapidly, before substantial weight loss—demonstrating the powerful role of food- and nutrient-driven gut signals in regulating whole-body metabolism, beyond the effects of surgically induced portion control alone.
This early metabolic transition may contribute to the subsequent weight-loss process and its long-term durability.
EL-924 is designed to recreate selected metabolic effects of bariatric surgery without surgery—by modulating food- and nutrient-driven gut signaling to improve metabolic health first, followed by weight loss.
By preserving adequate energy and nutritional intake during weight loss with early occurring metabolic improvements, EL-924 is designed to support lean mass preservation, physical and exercise performance, and quality of life. The platform has also been extensively engineered to improve gastrointestinal tolerability and minimize GI adverse effects.
The goal: Sustainable weight loss with metabolic health first, sustainable weight loss, and preservation of quality of life throughout the weight-loss journey.
How Our Platform Works
Following oral administration, Elaphron therapies form a locally acting, minimally absorbed protective hydrogel that transiently coats the gastrointestinal epithelium. Together with associated bioactive complexes, the hydrogel creates a novel interface between the intestinal surface and its luminal environment.
This interface is designed to modulate how nutrients, bile acids, and other luminal signals engage intestinal receptors, transporters, and signaling pathways—reshaping gut-derived metabolic signaling while acting primarily at the intestinal surface.
Beyond Obesity
The same platform can be engineered to protect the intestinal epithelium from an aggressive luminal environment and modulate local pathways involved in inflammation, mucosal injury, hypersecretion, and gastrointestinal dysfunction.
This creates opportunities for locally acting therapeutic approaches across a range of GI-driven conditions.
More than one billion people worldwide are living with obesity, a complex chronic disease and one of the largest unmet needs in global health.
Incretin-based therapies have transformed obesity treatment, demonstrating that substantial weight loss and meaningful cardiometabolic benefits are achievable.
However, translating this efficacy into durable population-level benefit remains challenging. Long-term persistence, treatment discontinuation and weight regain, tolerability, variable response, lean-mass preservation, cost and access, and the need for chronic therapy continue to leave important gaps.
The next generation of obesity therapies can build on this progress with complementary mechanisms that broaden treatment options beyond appetite suppression and weight loss alone—addressing the underlying biology of obesity and its associated metabolic dysfunction.
To establish a new therapeutic category for obesity and metabolic disease: oral, non-systemic therapies that act through the gastrointestinal tract without relying primarily on appetite suppression or chronic systemic exposure.
To translate the profound metabolic biology revealed by bariatric surgery into simple, oral, well-tolerated therapies that can be used at population scale.
The intestine is a key regulator of metabolic homeostasis. For decades, the only way to harness its profound metabolic effects was through bariatric/metabolic surgery.
The metabolic effects of bariatric surgery extend far beyond surgically induced dieting or portion control. Metabolic surgery changes how nutrients interact with the gastrointestinal tract, rapidly reshaping nutrient sensing, gut-derived hormonal and metabolic signaling, and whole-body metabolic regulation. Many of these effects emerge before substantial weight loss, demonstrating that the intestine itself is a powerful regulator of metabolic homeostasis.
Elaphron is developing oral, non-systemic locally acting therapies designed to target this biology without surgery. By modulating how luminal nutrients engage receptors, transporters, and signaling pathways in the proximal intestine, Elaphron aims to influence meal-driven gut–organ communication and reproduce selected metabolic effects associated with bariatric surgery—without an invasive procedure or chronic systemic drug exposure.
Local activity, minimal systemic exposure
Designed to improve metabolic regulation without relying on appetite suppression
Designed for use alone or alongside existing metabolic therapies
Our core team working together has repeatedly translated scientific invention into later clinical-stage therapies—conceiving new therapeutic approaches, developing enabling technologies, and advancing two first-in-class therapies from concept through Phase II, with one now progressing toward Phase III.
This track record has earned international recognition and support, including engagement with the WHO GTFCC and support from the European Union. It also led to a multinational consortium spanning 10 countries across three continents to advance a therapy based on our technology toward Phase III.
At Elaphron, we are applying this combination of scientific invention, technology development, and translational execution to advance a new generation of therapies for metabolic and gastrointestinal disease.
A rapidly emerging therapeutic field, supported by the profound metabolic outcomes observed following bariatric surgery and growing validation across multiple programs.
Inflammatory Bowel Disease IBD
Irritable Bowel Syndrome (IBS)&SIBO
